

<https://helda.helsinki.fi>

L1TD1-a prognostic marker for colon cancer

Chakroborty, Deepankar

2019-07-23

Chakroborty , D , Emani , M R , Klen , R , Bockelman , C , Hagström , J , Haglund , C ,
Ristimäki , A , Lahesmaa , R & Elo , L L 2019 , ' L1TD1-a prognostic marker for colon cancer
' , BMC Cancer , vol. 19 , 727 . <https://doi.org/10.1186/s12885-019-5952-2>

<http://hdl.handle.net/10138/306056>

<https://doi.org/10.1186/s12885-019-5952-2>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.


Please cite the original version.

RESEARCH ARTICLE

Open Access

L1TD1 - a prognostic marker for colon cancer



Deepankar Chakroborty^{1,2†}, Maheswara Reddy Emani^{1†}, Riku Klén^{1†}, Camilla Böckelman^{3,4}, Jaana Hagström^{3,5}, Caj Haglund^{3,4}, Ari Ristimäki^{6,7}, Riitta Lahesmaa^{1*†} and Laura L. Elo^{1*†} 

Abstract

Background: Prognostic markers specific to a particular cancer type can assist in the evaluation of survival probability of patients and help clinicians to assess the available treatment modalities.

Methods: Gene expression data was analyzed from three independent colon cancer microarray gene expression data sets ($N = 1052$). Survival analysis was performed for the three data sets, stratified by the expression level of the LINE-1 type transposase domain containing 1 (*L1TD1*). Correlation analysis was performed to investigate the role of the interactome of *L1TD1* in colon cancer patients.

Results: We found *L1TD1* as a novel positive prognostic marker for colon cancer. Increased expression of *L1TD1* associated with longer disease-free survival in all the three data sets. Our results were in contrast to a previous study on medulloblastoma, where high expression of *L1TD1* was linked with poor prognosis. Notably, in medulloblastoma *L1TD1* was co-expressed with its interaction partners, whereas our analysis revealed lack of co-expression of *L1TD1* with its interaction partners in colon cancer.

Conclusions: Our results identify increased expression of *L1TD1* as a prognostic marker predicting longer disease-free survival in colon cancer patients.

Keywords: Human *L1TD1* gene, Colon cancer, Prognostic factors, Biomarkers, Survival analysis

Background

Colon cancer is the third leading cancer, both in terms of newly diagnosed cases and mortality [1]. Despite the fact that chemotherapeutic agents, such as oxaliplatin and irinotecan, have markedly improved the survival rate in colon cancer [2], identification of patients likely to respond well to chemotherapy could increase the survival rate. Our study identifies LINE-1 type transposase domain containing 1 (*L1TD1*) as a novel positive prognostic marker for colon cancer.

Stem cell-like gene signatures have been detected in various cancers [3, 4], and embryonic stem cell factors have been associated with enhanced tumorigenesis and poor prognosis [5–7]. *L1TD1* is an RNA-binding protein required

for self-renewal of undifferentiated embryonic stem cells [8]. Recently, *L1TD1* protein was shown to form a core interaction network with the canonical pluripotency factors OCT4, NANOG, LIN28, and SOX2 in human embryonic stem cells (hESCs) [9], and *L1TD1* depletion resulted in downregulation of the pluripotency markers OCT4, NANOG, and LIN28 in hESCs [10]. *L1TD1* has previously been shown to be essential for self-renewal of embryonal carcinoma cells [10] and to support the growth of seminoma cells [10].

We studied *L1TD1* immunoexpression in colon adenocarcinoma tissue sections and analyzed three independent gene expression microarray data sets of colon cancer patients to assess the prognostic significance of *L1TD1* in colon cancer [11–13]. Our findings suggest that *L1TD1* is a promising prognostic marker for colon cancer.

* Correspondence: riitta.lahesmaa@utu.fi; laura.elo@utu.fi

[†]Deepankar Chakroborty, Maheswara Reddy Emani, and Riku Klén should be considered equal first authors.

[†]Riitta Lahesmaa and Laura L. Elo should be considered equal senior authors.

¹Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland

Full list of author information is available at the end of the article



Methods

Microarray data sets

Raw microarray data sets (Table 1) were downloaded from Gene Expression Omnibus (GEO) [17]. Three colon cancer gene expression microarray data sets comprising a total of 1052 clinical samples were analyzed [11–13]. Either due to non-tumoral origin (i.e. normal tissue) or due to missing associated survival information, 124 samples had to be excluded from the survival analysis (928 samples remained). Additionally, two seminoma [14, 15] and one stem cell [16] gene expression microarray data sets were analyzed to assess the co-expression of *L1TD1* and its interaction partners (Additional file 2: Table S1). The stem cell data set was composed of samples from ten hESCs, 49 induced pluripotent stem cells (iPSCs), five cancer cell lines, and six non-cancerous somatic cell lines. A summary of the data sets used is presented in Table 1.

Gene expression analysis

The CEL files, containing the probe intensity measurements of the Affymetrix probes were normalized using the Universal exPRession Code (UPC) normalization method from the Bioconductor package “SCAN.UPC” [18] and the Robust Multiarray Average (RMA) normalization method from the Bioconductor package “affy” [19, 20]. The UPC normalization method provides a score between 0.0 and 1.0, which represents the probability of a particular gene being expressed in a particular sample [18]. The UPC scores were used to categorize the samples in all data sets based on their *L1TD1* expression status as *L1TD1* high (UPC \geq 0.60) and *L1TD1* low (UPC $<$ 0.60). The UPC threshold of 0.6 was determined by calculating a weighted mean (by sample size) of the local minima between the two peaks in the bimodal distributions of UPC scores for *L1TD1* over the three colon cancer data sets (Additional file 1: Fig. S1). RMA provides normalized log₂ intensity values. RMA normalized gene expression values were used to calculate pairwise correlations between genes. To correct for multiple testing, the false discovery rate (FDR) was controlled using the Benjamini-Hochberg procedure [21]. The probe “219955_at” was chosen as the primary probe

for the quantification of *L1TD1* because it was present in both of the Affymetrix platforms used in this study (HG-U133Plus2 and HG-U133A).

Gene list descriptions

Interaction partners

The 311 interaction partners of *L1TD1* were determined using mass spectrometry and co-immunoprecipitation in our earlier study [9]. 306 interaction partners of *L1TD1* were identified by performing a mass spectrometry analysis on co-immunoprecipitated proteins with two different anti-*L1TD1* antibodies (recognizing different epitopes on *L1TD1*). In addition, for 5 proteins (NANOG, OCT4 (POU5F1), SOX2, DNMT3B, and TRIM28) that were challenging to detect using mass spectrometry, the interactions were shown using immunoprecipitation and Western blotting. Out of the 311 interaction partners, 285 corresponded to genes that had probes associated to them in the microarray platforms used in this study.

Top 20 interaction partners

The top 20 interaction partners of *L1TD1* were determined on the basis of their co-expression with *L1TD1* in the seminoma and stem cell data sets. First, the interaction partners were ranked in descending order of their Spearman rank correlation value with *L1TD1* in these data sets. Then, the maximum rank over the data sets was selected as a representative statistic for each interaction partner. The list was ordered (ascending) based on this maximum rank and 20 interaction partners were selected from the top of the list.

Top 20 co-expressed genes with *L1TD1* in colon cancer

Out of all the genes in the microarray data sets (27213 unique probe-gene mappings), top 20 genes were selected based on their co-expression with *L1TD1* in the colon cancer data sets. First, all the genes in the microarray data sets were ranked in descending order of their Spearman rank correlation value with *L1TD1* separately for each colon cancer data set. Then, the maximum rank over these data sets was selected as a representative

Table 1 Summary of the data sets used in the study. The GEO accession numbers (GEO ID) are listed together with alias names used to refer to the individual data sets, the microarray platform, the total number of samples, and the number of samples used in the survival analysis

GEO ID	Total Samples	Survival Analysis	Platform	Alias
GSE14333 [11]	290	226	Affymetrix HG-U133Plus2	colon1
GSE17536 [12]	177	145	Affymetrix HG-U133Plus2	colon2
GSE39582 [13]	585	557	Affymetrix HG-U133Plus2	colon3
GSE3218 [14]	107	Not used	Affymetrix HG-U133A	seminoma1
GSE10783 [15]	34	Not used	Affymetrix HG-U133A	seminoma2
GSE42445 [16]	70	Not used	Agilent-028004 SurePrint G3 Human GE 8x60K	hESC1

statistic for each gene. The list was ordered (ascending) based on this maximum rank and 20 genes were selected from the top of the list.

Survival analysis of microarray data

Disease-free survival was analyzed in each data set with the Kaplan-Meier method as implemented in the R package “survival” [22, 23] and survival curves were plotted using the R package “survminer” [24]. The log-rank test was used to compare survival rates between the two *LITD1* groups (*LITD1* high and *LITD1* low).

Association between *LITD1* expression and clinicopathological variables

We investigated the association of age and sex and other publicly accessible clinicopathological variables to the *LITD1* gene expression in the three gene expression data sets. The variables included cancer stage [11–13], prior-therapy received by the patients [11–13], tumor location [11–13], chromosomal instability [13], CpG island methylation status [13], DNA mismatch repair proficiency [13], mutation status of BRAF (B-Raf proto-oncogene, serine/threonine kinase), mutation status of KRAS (KRAS proto-oncogene, GTPase), and mutation status of TP53 (Tumor Protein p53) [13]. For variables with only two categories, Wilcoxon rank sum test [25] was used for the analysis of statistical significance. For variables with more than two categories, Kruskal-Wallis test [26] was used. Association of *LITD1* expression with age was investigated using Pearson correlation [27].

Analysis of TCGA Colon adenocarcinoma RNA-seq data set

RNA-seq data from The Cancer Genome Atlas Colon Adenocarcinoma [28] (TCGA-COAD) data set was acquired from Genomic Data Commons (portal.gdc.cancer.gov). The FPKM-UQ normalized (Fragments Per Kilobase of transcript per Million mapped reads Upper Quartile) RNA-seq counts from the primary tumor samples ($N = 521$) were used to validate the correlation analyses performed using the microarray data sets. Due to lack of an evident choice of the intensity threshold to designate samples into high and low *LITD1* expression groups, we fitted a mixture of two Gaussian distributions and evaluated two different thresholds (Additional file 1: Figure S2): FPKM-UQ value where the ratio of the two Gaussian distributions was equal, and FPKM-UQ value where the ratio of the two Gaussian distributions was 10%. These two thresholds were then used to perform survival analysis using disease-free survival with Kaplan-Meier method.

Results

High expression of *LITD1* associates with longer disease-free survival

Across the three colon cancer microarray data sets, 26.7% of the colon cancer patients were categorized to have high *LITD1* expression (Table 2, Additional file 1: Figure S3). The proportion was lower than that observed in seminoma (48.6 and 50%) and stem cell (88.6%) data sets (Table 2, Additional file 1: Figure S3).

Kaplan-Meier analysis of 928 samples from the three colon cancer data sets revealed that the colon cancer samples with high *LITD1* expression had longer disease-free survival as compared to those with no/low *LITD1* expression (Fig. 1). The difference was statistically significant in all the three data sets (log-rank test $P < 0.05$).


LITD1 expression was higher in the samples from early cancer stages as compared to those from later stages in all the three data sets ($P < 0.05$), whereas differences between the later stages were typically not statistically significant (Additional file 1: Figure S4A–C). In the dataset colon3, *LITD1* expression was high for samples with mutated KRAS ($P < 0.0001$), wild-type TP53 ($P < 0.0001$), and negative chromosomal instability marker ($P < 0.0001$) (Additional file 1: Figure S4D–F). Additionally, significant associations were observed between *LITD1* expression and tumor location or tumor differentiation status ($P < 0.0001$) (Additional file 1: Figure S4G–I). Age, sex, prior therapy (chemo-, radio- or adjuvant therapy), BRAF mutation status, CpG island methylation status, or DNA mismatch repair proficiency did not show statistically significant associations with the *LITD1* expression (Additional file 1: Figure S5).

Interactome of *LITD1* is not co-expressed in colon cancer

To examine the potential role of the previously identified interaction partners of *LITD1* [9] (Additional file 2: Table S1) in its prognostic performance in colon cancer, Spearman rank correlation matrices were calculated

Table 2 Proportion of samples with high expression of *LITD1*. The samples were categorized based on their *LITD1* expression level (high *LITD1*+ or low *LITD1*-) in the different data sets used in this study. For the colon cancer data sets, only tumor samples with complete survival information were considered

Data set	<i>LITD1</i> +	<i>LITD1</i> -	Total	Percentage of <i>LITD1</i> +
colon1	64	162	226	28.3%
colon2	44	101	145	30.3%
colon3	140	417	557	25.1%
Total (Colon Cancer)	248	680	928	26.7%
seminoma1	52	55	107	48.6%
seminoma2	17	17	34	50.0%
hESC1	62	8	70	88.6%



between the expression levels of *LITD1* and its interaction partners [9]. Interestingly, the high positive correlation observed among *LITD1* and its top 20 interaction partners in seminoma and stem cell data sets ($P < 0.0001$, Fig. 2a) was absent in all three colon cancer data sets (Fig. 2b). However, the interaction partners did not consistently improve the predictive prognostic power obtained with *LITD1* alone (Additional file 2: Table S2).

Genes co-expressed with *LITD1* in colon cancer

We identified genes that were co-expressed with *LITD1* in colon cancer patients using Spearman rank correlation (Table 3, Additional file 2: Table S3). Although none of the top 20 co-expressed genes outperformed *LITD1* as independent prognostic marker for colon cancer in all the three data sets, five genes had statistically significant ($P < 0.05$) impact on survival in at least two out of the three colon cancer data sets (Table 4): Serine peptidase inhibitor Kazal type 4 (*SPINK4*), Resistin-like beta (*RETNLB*), Asparaginase-like 1 Protein (*ASRGL1*), Chloride channel accessory 1 (*CLCA1*), and Fc fragment of IgG binding protein (*FCGBP*) (Additional file 1: Figure S6).

Validation in TCGA Colon adenocarcinoma RNA-seq data set

To further validate our findings from the three colon cancer microarray data sets, we analyzed the TCGA Colon Adenocarcinoma [28] (TCGA-COAD) RNA-seq data set containing 521 patient samples. When the samples were stratified for *LITD1* expression using the threshold where the ratio of the two Gaussian distributions was 10%, Kaplan-Meier analysis supported that the

colon cancer samples with high *LITD1* expression had longer disease-free survival as compared to those with no/low *LITD1* expression ($P = 0.038$, Additional file 1: Figure S2C). Additionally, we were able to reproduce the findings from the correlation analyses, indicating a lack of correlation between *LITD1* and its top 20 interaction partners (Additional file 1: Figure S2D) and confirming significant correlations between *LITD1* and genes that were co-expressed with *LITD1* in the colon cancer microarray data sets (Additional file 1: Figure S2E).

Discussion

In this study, we examined the prognostic value of *LITD1* in colon cancer patients. We found compelling evidence of *LITD1* being a positive prognostic marker for colon cancer (Fig. 1). We demonstrated this by survival analysis of 928 samples from three independent gene expression data sets of colon cancer patients and further confirmed the results in the TCGA Colon Adenocarcinoma RNA-seq data set of 521 colon cancer patients.

Expression of *LITD1* has earlier been reported to be highly specific to embryonic stem cells [10], brain [29], and colon (Additional file 1: Figure S7). Besides these healthy tissues, *LITD1* expression has also been reported in seminoma [10], embryonic carcinomas [10], medulloblastoma [30], and colon adenocarcinoma (Additional file 1: Figures S3 and S7). Expression of *LITD1* at high levels in colon cancer cells led us to hypothesize that high expression of *LITD1* in colon cancer might be associated with prognosis. Earlier reports have demonstrated the association of stem cell pluripotency factors with poor prognosis in different cancer types,




Fig. 2 (See legend on next page.)

(See figure on previous page.)

Fig. 2 Co-expression of interaction partners of *LITD1*. Heatmaps showing signed *P*-value of Spearman rank correlation for the 20 most significantly co-expressed interaction partners of *LITD1* determined on the basis of the seminoma and stem cell data sets. Co-expression in (a) seminoma and stem cell data sets, and (b) colon cancer data sets. The signed *P*-value of Spearman rank correlation was defined as $1 - P$ -value of Spearman rank correlation multiplied by the sign of the correlation

including medulloblastoma [30] and seminoma [15]. Interestingly, our results were in contrast with previous studies, suggesting that in colon cancer, high expression of *LITD1* is linked to better prognosis. In the three colon cancer data sets, expression of *LITD1* was associated with samples of low clinical cancer stage (Additional file 1: Figure S4A-C), which can perhaps be a reason for its prognostic significance.

In an attempt to understand the distinctive role of *LITD1* in different cancers, we investigated the co-expression of *LITD1* with its currently known interaction partners. We discovered that, unlike in hESCs and seminomas, *LITD1* was not co-expressed with its interaction partners in colon cancer (Fig. 2). This points to the potential participation of *LITD1*'s interaction partners in the contrasting prognostic outcome. This was further supported by a recent study in medulloblastoma,

showing an association of high *LITD1* expression with poor clinical outcome and significant co-expression between *LITD1* and its interaction partner *OCT4* [30]. Together, these findings suggest that the co-expression of *LITD1* with its interaction partners might be required for manifesting an aggressive and detrimental phenotype. This is the first time that an embryonic stem cell factor has been shown to lead to contrasting outcomes in cancer, taking into consideration to the presence or absence of strong co-expression with its interaction partners.

We also investigated genes that were co-expressed with *LITD1* in colon cancer. Among the top 20 co-expressed genes, six had previously been linked to colon cancer. Chloride Channel Accessory 1 (*CLCA1*) is a tumor suppressor protein that regulates differentiation and proliferation of colorectal cancer cells. Its low

Table 3 Top 20 co-expressed genes with *LITD1* in colon cancer. The Spearman rank correlation values (r_s) with *LITD1* are shown together with their false discovery rates (FDR) separately for each colon cancer data set

Rank	Gene Name	colon 1		colon 2		colon 3	
		r_s	FDR	r_s	FDR	r_s	FDR
1	<i>RETNLB</i>	0.47	9.26E-13	0.53	3.69E-10	0.45	0.00
2	<i>CLCA1</i>	0.45	5.65E-12	0.43	1.10E-05	0.45	0.00
3	<i>HEPACAM2</i>	0.43	1.05E-10	0.41	3.98E-05	0.46	0.00
4	<i>FOXA3</i>	0.41	1.14E-09	0.43	1.06E-05	0.43	0.00
5	<i>FCGBP</i>	0.41	1.14E-09	0.39	2.15E-04	0.47	0.00
6	<i>ST6GALNAC1</i>	0.40	4.55E-09	0.39	1.87E-04	0.43	2.57E-24
7	<i>SPINK4</i>	0.44	2.99E-11	0.38	3.91E-04	0.43	5.06E-25
8	<i>KIAA1324</i>	0.40	4.60E-09	0.44	7.71E-06	0.39	0.00
9	<i>KLF4</i>	0.40	4.60E-09	0.37	4.61E-04	0.41	0.00
10	<i>GMDS</i>	0.46	1.50E-12	0.40	9.95E-05	0.38	0.00
11	<i>SLITRK6</i>	0.43	5.87E-11	0.36	1.14E-03	0.46	0.00
12	<i>SERPINA1</i>	0.42	1.35E-10	0.38	3.84E-04	0.35	1.26E-16
13	<i>LINC00261</i>	0.34	1.45E-06	0.35	2.09E-03	0.48	0.00
14	<i>ITLN1</i>	0.35	4.43E-07	0.33	3.97E-03	0.42	0.00
15	<i>MUC2</i>	0.39	8.64E-09	0.33	4.90E-03	0.38	0.00
16	<i>DEFA5</i>	0.37	5.72E-08	0.35	1.78E-03	0.33	6.77E-14
17	<i>ASRGL1</i>	0.40	4.55E-09	0.32	6.22E-03	0.41	0.00
18	<i>SLC27A2</i>	0.36	2.17E-07	0.36	9.05E-04	0.33	2.44E-13
19	<i>RNF186</i>	0.32	8.44E-06	0.36	1.30E-03	0.34	1.89E-14
20	<i>PCCA</i>	0.37	1.05E-07	0.37	7.52E-04	0.33	2.95E-13

Table 4 Prognostic assessment of genes that co-express with *LITD1* in colon cancer

Gene	colon1	colon2	colon3
<i>LITD1</i>	<u>0.009729</u>	<u>0.008520</u>	<u>0.018607</u>
<i>SPINK4</i>	<u>0.007148</u>	<u>0.001854</u>	0.880992
<i>RETNLB</i>	0.325642	<u>0.012519</u>	<u>0.009064</u>
<i>ASRGL1</i>	<u>0.015986</u>	0.521116	<u>0.016293</u>
<i>CLCA1</i>	<u>0.030053</u>	<u>0.006496</u>	0.710961
<i>FCGBP</i>	<u>0.028617</u>	<u>0.047080</u>	0.292182
<i>ITLN1</i>	0.088225	0.043802	0.844453
<i>FOXA3</i>	0.077752	0.609721	0.093598
<i>PCCA</i>	0.064797	0.601176	0.107992
<i>DEFA5</i>	0.136904	0.157008	0.737800
<i>GMDS</i>	0.318171	0.170255	0.000919
<i>HEPACAM2</i>	0.368837	0.687066	0.098125
<i>SERPINA1</i>	0.000008	0.493419	0.911649
<i>RNF186</i>	0.700045	0.541107	0.010793
<i>KLF4</i>	0.938136	NA	0.220231
<i>ST6GALNAC1</i>	0.593332	0.880638	0.030027
<i>MUC2</i>	0.624983	0.505661	0.842770
<i>KIAA1324</i>	0.220079	0.969530	0.730810
<i>SLITRK6</i>	0.750696	0.894483	0.085490
<i>LINC00261</i>	0.823520	0.823442	0.269044
<i>SLC27A2</i>	0.883481	0.975288	0.002906

Statistical significance of the top 20 co-expressed genes in the survival analysis of colon cancer patients in the three data sets. Genes with statistically significant association with disease-free survival (log-rank test $P < 0.05$) in at least two colon cancer data sets are underlined

expression has been associated with tumorigenesis, metastasis, and chromosomal instability, as well as poor prognosis in colorectal cancer [31]. Kruppel Like Factor 4 (*KLF4*) is a target of the tumor suppressor gene Adenomatous Polyposis Coli (*APC*) and its overexpression reduces cell migration and invasion in vitro and tumorigenicity of colon cancer cells in vivo [32]. GDP-mannose-4,6-dehydratase (*GMDS*) has been shown to have exon deletions linked to progression of colorectal cancer [33]. Also, an in vitro study found that *GMDS* deficiency in colon cancer cells made them resistant to receptor-mediated apoptosis [34]. High expression of Mucin 2 (*MUC2*) has been associated with longer disease-free survival in colorectal cancer patients [35]. Frameshift mutations resulting in premature termination of translation of Propionyl-CoA Carboxylase Alpha Subunit (*PCCA*) have been reported in colon and gastric cancer [36]. Investigation of the potential role of Alpha-1-antitrypsin (*SERPINA1*) expression in cancers provides controversial results; it has been associated with good prognosis in breast and colon cancer on protein atlas [37] (<https://www.proteinatlas.org/ENSG00000197249-SERPINA1/pathology>), but there are also reports that associate it with poor prognosis in colon cancer [38], gastric cancer [39] and cutaneous squamous cell carcinoma [40].

Several of the co-expressed genes have been linked to various other cancers. Down-regulation of Fc fragment of IgG binding protein (*FCGBP*) has been associated with decreased overall survival in gallbladder adenocarcinoma [41] and with progression of prostate cancer in Transgenic adenocarcinoma Mouse Prostate (*TRAMP*) [42]. Upregulation of ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (*ST6GALNAC1*) has been associated with good prognosis in breast cancer [43]. Additionally, siRNA-mediated silencing of *ST6GALNAC1* has been shown to lead to reduced growth, migration and invasion of gastric cancer cells in vitro [44]. Estrogen-Induced Gene 121 Protein (*KIAA1324*), Long Intergenic Non-Protein Coding RNA 261 (*LINC00261*), and Intelectin 1 (*ITLN1*) have been shown to function as tumor suppressors in gastric cancer, with decreased expression associated with poor prognosis [45–47]. Low expression of Asparaginase-Like 1 Protein (*ASRGL1*) has been suggested as a marker for poor prognosis in endometrial carcinoma [48], whereas reduced levels of Solute carrier family 27 member 2 (*SLC27A2*) have been associated with poor survival in lung cancer [49]. SLIT and NTRK-like protein 6 (*SLITRK6*) is a known bladder tumor antigen, and is currently under investigation in clinical trials as a target for antibody-drug conjugate therapy [50]. *HEPACAM* family member 2 (*HEPACAM2*) is a paralog of Hepatocyte Cell Adhesion Molecule (*HEPACAM*), which is known to act as a tumor suppressor by promoting differentiation [51].

HEPACAM2, however, is a relatively newly-identified molecule and is not well-studied.

Conclusion

Our study of gene expression data from four clinical colon cancer data sets produced promising evidence in support of *L1TD1* as a marker for good prognosis in colon cancer. Our results emphasize the need for further investigation and validation of *L1TD1* as a potential prognostic marker in larger cohorts of colon cancer. Finally, this work also underscores the potential merits of investigating co-expressed genes to markers of interest.

Additional files

Additional file 1: Figure S1. Density distributions of UPC scores for *L1TD1* in the three colon cancer microarray data sets. A dashed black line indicates the UPC threshold of 0.6, which was used to stratify the samples into *L1TD1*+ and *L1TD1*- groups in the three data sets. **Figure S2.** Analysis of the primary tumor samples in The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) data set. **(A)** Estimation of FPKM-UQ normalized RNA-seq counts by fitting Gaussian distributions. **(B–C)** Kaplan-Meier curves using the two thresholds for designating *L1TD1* high and low samples (grey and red dashed lines, respectively). **(D)** Heatmaps showing signed P-value of Spearman rank correlation for the 20 most significantly co-expressed interaction partners of *L1TD1*. **(E)** The Spearman rank correlation values (*r*s) between *L1TD1* and its top 20 co-expressed genes (Table 3). The correlations in the TCGA-COAD data set are shown with their false discovery rate (FDR). **Figure S3.** Heatmaps showing expression level of *L1TD1* and its top 20 interaction partners in the samples of **(A)** colon cancer data sets, and **(B)** seminoma and stem cell data sets. **Figure S4.** Boxplots of UPC scores of *L1TD1* stratified based on the indicated clinicopathological parameters in the different colon cancer microarray data sets. **Figure S5.** Boxplots of UPC scores of *L1TD1* stratified based on the indicated clinicopathological parameters in the different colon cancer microarray data sets. **Figure S6.** Kaplan-Meier curves showing disease-free survival for the three colon cancer data sets (columns). The curves present survival data for the two groups of colon cancer patients based on gene expression level (high or low) of *SPINK4*, *RETNLB*, *ASRGL1*, *CLCA1*, and *FCGBP* (rows). Grey = high gene expression, Black = low gene expression. **Figure S7.** Formalin-fixed and paraffin-embedded tissue microarray blocks were stained with immunohistochemistry using anti-*L1TD1* (Atlas Antibodies, HPA028501). **(A)** Normal colon tissue, **(B)** colorectal adenocarcinoma sample. (PDF 2132 kb)

Additional file 2: Table S1. 311 Interaction partners of *L1TD1* were determined using Mass spectrometry and co-immunoprecipitation in our earlier publication (Emami, Närvä, 2015, Stem cell reports). 306 Interaction partners of *L1TD1* were identified by performing a Mass spectrometry analysis on co-immunoprecipitated proteins with two different anti-*L1TD1* antibodies (recognizing different epitopes on *L1TD1*). In addition, we included 5 more proteins (*NANOG*, *OCT4* (*POU5F1*), *SOX2*, *DNMT3B*, and *TRIM28*) that were challenging to detect using Mass spectrometry but the interactions were shown using Immunoprecipitation and Western Blotting. This makes a total of 311 proteins that are referred to in this work as “Interaction partners” of *L1TD1*. **Table S2.** Colon cancer samples with a high *L1TD1* expression and a concomitant lack of expression of the listed interaction partner were compared to colon cancer samples with a low *L1TD1* expression in the three data sets, this table lists the *P*-values (log-rank test) for these comparisons. *P*-value less (more significant) than the one obtained by comparing *L1TD1* high and low sample groups are highlighted. **Table S3.** Table lists the 20 genes that had a positive correlation with *L1TD1* in the colon cancer

data sets. The table lists their UNIPROT ID and UNIRPOT protein name. (PDF 211 kb)

Abbreviations

APC: Adenomatous Polyposis Coli; ASRGL1: Asparaginase-like 1 Protein; CLCA1: Chloride channel accessory 1; DNMT3B: DNA (cytosine-5)-methyltransferase 3B; FCGBP: Fc fragment of IgG binding protein; FDR: False discovery rate; GEO: Gene Expression Omnibus; GMDs: GDP-mannose-4,6-dehydratase; HEPACAM: Hepatocyte Cell Adhesion Molecule; HEPACAM2: HEPACAM family member 2; hESC: Human embryonic stem cell; iPSCs: Induced pluripotent stem cell; ITLN1: Intelectin 1; KIAA1324: Estrogen-Induced Gene 121 Protein; KLF4: Kruppel Like Factor 4; L1TD1: LINE-1 type transposase domain containing 1; LIN28: Protein lin-28 homolog A; LINC00261: Long Intergenic Non-Protein Coding RNA 261; MUC2: Mucin 2; NANOG: Homeobox protein NANOG; OCT4: POU domain, class 5, transcription factor 1; PCCA: Propionyl-CoA Carboxylase Alpha Subunit; RETNLB: Resistin-like beta; RMA: Robust Multitarray Average; SERPINA1: Alpha-1-antitrypsin; SLC27A2: Solute carrier family 27 member 2; SLITRK6: SLIT and NTRK-like protein 6; SOX2: Transcription factor SOX-2; SPINK4: Serine peptidase inhibitor Kazal type 4; ST6GALNAC1: ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1; TRAMP: Transgenic adenocarcinoma Mouse Prostate; TRIM28: Transcription intermediary factor 1-beta; UPC: Universal exPression Code

Acknowledgements

We would like to thank the funding agencies supporting the study. We would also like to thank Dr. Aidan McGlinchey for proofreading the manuscript.

Author contributions

Conceptualization: MRE, CH, AR, RL, LLE; Methodology: DC, MRE, RK, CB, JH, CH, AR, RL, LLE; Investigation: DC, RK, CB, JH; Formal analysis: DC, RK, CB; Visualization: DC, RK; Writing – original draft: DC; Writing – review and editing: DC, RK, CB, CH, LLE; Supervision: RL, LLE; Funding Acquisition: MRE, CH, AR, RL, LLE; All authors have read and approved the manuscript.

Funding

DC has been supported by University of Turku and University of Turku Graduate School. MRE has been supported by the Academy of Finland (265723). CH and AR have received financial support from the Sigrid Jusélius Foundation, the Finnish Cancer Foundation, Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. RL has been supported by the Academy of Finland, AoF, Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012–2017) grant 250114; by the AoF grants 292335, 294337, 319280, 292482, 31444, and by grants from the Sigrid Jusélius Foundation (SJF) and the Finnish Cancer Foundation. LLE reports grants from the European Research Council ERC (677943), European Union's Horizon 2020 research and innovation programme (675395), Academy of Finland (296801, 304995, 310561 and 313343), Juvenile Diabetes Research Foundation JDRF (2–2013-32), Tekes – the Finnish Funding Agency for Innovation (1877/31/2016), and Sigrid Juselius Foundation, during the conduct of the study. The funding bodies had no role in the study design, data collection and analysis, interpretation of the data and results, or in writing the manuscript.

Availability of data and materials

All requests for access to data and material are to be addressed jointly to Riitta Lahesmaa and Laura L. Elo. Publicly available datasets can be accessed at Gene Expression Omnibus (GEO IDs listed in Table 1).

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

There are no financial or non-financial competing interests.

Author details

¹Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. ²Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland. ³Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland. ⁴Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁵Department of Pathology and Oral Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁶Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. ⁷Genome-Scale Biology Research program, University of Helsinki, 00290 Helsinki, Finland.

Received: 19 December 2018 Accepted: 18 July 2019

Published online: 23 July 2019

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018; 68:7–30. <https://doi.org/10.3322/caac.21442>.
- Wilson PM, Ladner RD, Lenz H-J. Predictive and prognostic markers in colorectal cancer. *Gastrointest Cancer Res*. 2007;1:237–46.
- Atlati Y, Mowla SJ, Ziaee SAM, Bahrami A-R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. *Int J Cancer*. 2007;120:1598–602. <https://doi.org/10.1002/ijc.22508>.
- Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet*. 2008;40:499–507. <https://doi.org/10.1038/ng.127>.
- Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. *Clin Cancer Res*. 2008;14:4085–95.
- Meng H-M, Zheng P, Wang X-Y, Liu C, Sui H-M, Wu S-J, et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. *Cancer Biol Ther*. 2010;9:295–302. <https://doi.org/10.4161/cbt.9.4.10666>.
- Lu X, Mazur SJ, Lin T, Appella E, Xu Y. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. *Oncogene*. 2014;33:2655–64. <https://doi.org/10.1038/onc.2013.209>.
- Wong RC-B, Ibrahim A, Fong H, Thompson N, Lock LF, Donovan PJ. L1TD1 is a marker for undifferentiated human embryonic stem cells. *PLoS One*. 2011;6:e19355. <https://doi.org/10.1371/journal.pone.0019355>.
- Emani MRR, Närvä E, Stubb A, Chakroborty D, Viitala M, Rokka A, et al. The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotency. *Stem Cell Reports*. 2015;4:519–28. <https://doi.org/10.1016/j.stemcr.2015.01.014>.
- Närvä E, Rahkonen N, Emani MR, Lund R, Pursiheimo JP, Nästi J, et al. RNA-binding protein L1TD1 interacts with LIN28 via RNA and is required for human embryonic stem cell self-renewal and cancer cell proliferation. *Stem Cells*. 2012;30:452–60. <https://doi.org/10.1002/stem.1013>.
- Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. *Clin Cancer Res*. 2009; 15:7642–51.
- Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with Colon Cancer. *Gastroenterology*. 2010;138:958–68. <https://doi.org/10.1053/j.gastro.2009.11.005>.
- Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of Colon Cancer into molecular subtypes: characterization, validation, and prognostic value. *PLoS Med*. 2013;10: e1001453. <https://doi.org/10.1371/journal.pmed.1001453>.
- Korkola JE, Houldsworth J, Chadalavada RSV, Olshen AB, Dobrzynski D, Reuter VE, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. *Cancer Res*. 2006;66:820–7. <https://doi.org/10.1158/0008-5472.CAN-05-2445>.
- Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin L-X, Patil S, et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. *J Clin Oncol*. 2009;27:5240–7. <https://doi.org/10.1200/JCO.2008.20.0386>.
- Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, Sawamura Y, et al. Differentiation-defective phenotypes revealed by large-scale analyses of

- human pluripotent stem cells. *Proc Natl Acad Sci U S A*. 2013;110:20569–74. <https://doi.org/10.1073/pnas.1319061110>.
17. Edgar R. Gene expression omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res*. 2002;30:207–10. <https://doi.org/10.1093/nar/30.1.207>.
 18. Piccolo S, Withers M. Multiplatform single-sample estimates of transcriptional activation. *Proc Natl Acad Sci U S A*. 2013;110:17778–83. <https://doi.org/10.1073/pnas.1305823110>.
 19. Irizarry R, Hobbs B, Collin F. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003;4:249–64.
 20. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy—analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics*. 2004;20:307–15. <https://doi.org/10.1093/bioinformatics/btg405>.
 21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B*. 1995;57:289–300.
 22. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer; 2000.
 23. Therneau TM. A package for survival analysis in S; 2015.
 24. Kassambara A, Kosinski M. survminer: Drawing Survival Curves using “ggplot2.” 2016.
 25. Wilcoxon F. Individual comparisons by ranking methods. *Biom Bull*. 1945;1: 80. <https://doi.org/10.2307/3001968>.
 26. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. *J Am Stat Assoc*. 1952;47:583–621. <https://doi.org/10.1080/01621459.1952.10483441>.
 27. Pearson K. Notes on regression and inheritance in the case of two parents. *Proc R Soc London*. 1895;58:240–2. <https://doi.org/10.1098/rpsl.1895.0041>.
 28. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et al. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012;487:330–7. <https://doi.org/10.1038/nature11252>.
 29. Iwabuchi K a, Yamakawa T, Sato Y, Ichisaka T, Takahashi K, Okita K, et al. ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency. *PLoS One*. 2011;6:e20461. <https://doi.org/10.1371/journal.pone.0020461>.
 30. Santos MCT, Silva PBG, Rodini CO, Furukawa G, Marco Antonio DS, Zanutto-Filho A, et al. Embryonic stem cell-related protein L1TD1 is required for cell viability, Neurosphere formation, and Chemoresistance in Medulloblastoma. *Stem Cells Dev*. 2015;24:150810085436001. <https://doi.org/10.1089/scd.2015.0052>.
 31. Yang B, Cao L, Liu J, Xu Y, Milne G, Chan W, et al. Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer. *Cancer*. 2015;121:1570–80. <https://doi.org/10.1002/cncr.29235>.
 32. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenicity. *Oncogene*. 2003;22:3424–30.
 33. Nakayama K, Moriwaki K, Imai T, Shinzaki S, Kamada Y, Murata K, et al. Mutation of GDP-mannose-4,6-dehydratase in colorectal cancer metastasis. *PLoS One*. 2013;8:e70298. <https://doi.org/10.1371/journal.pone.0070298>.
 34. Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMD5) deficiency renders Colon Cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. *J Biol Chem*. 2011;286: 43123–33. <https://doi.org/10.1074/jbc.M111.262741>.
 35. Hsu H-P, Lai M-D, Lee J-C, Yen M-C, Weng T-Y, Chen W-C, et al. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. *Sci Rep*. 2017;7:5823. <https://doi.org/10.1038/s41598-017-04952-7>.
 36. Oh HR, Kim MS, YOO NJ, Lee SH. Frameshift mutations of OGDH, PPAT and PCCA genes in gastric and colorectal cancers. *Neoplasma*. 2016;63. https://doi.org/10.4149/neo_2016_504.
 37. Uhlén M, Björling E, Agaton C, Szilyarto CA-K, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. *Mol Cell Proteomics*. 2005;4:1920–32. <https://doi.org/10.1074/mcp.M500279-MCP200>.
 38. Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK. Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. *Oncotarget*. 2014;6.
 39. Kwon CH, Park HJ, Lee JR, Kim HK, Jeon TY, Jo H-J, et al. Serpin peptidase inhibitor clade a member 1 is a biomarker of poor prognosis in gastric cancer. *Br J Cancer*. 2014;111:1993–2002. <https://doi.org/10.1038/bjc.2014.490>.
 40. Farshchian M, Kivisaari A, Ala-aho R, Riihilä P, Kallajoki M, Grénman R, et al. Serpin peptidase inhibitor clade a member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. *Am J Pathol*. 2011;179:1110–9. <https://doi.org/10.1016/j.ajpath.2011.05.012>.
 41. Xiong L, Wen Y, Miao X, Yang Z. NTSE and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. *Cell Tissue Res*. 2014;355:365–74.
 42. Gazi MH, He M, Cheville JC, Young CYF. Downregulation of IgG fc binding protein (fc gammaBP) in prostate cancer. *Cancer Biol Ther*. 2008;7:70–5. <https://doi.org/10.4161/cbt.7.1.5131>.
 43. Patani N, Jiang W, Mokbel K. Prognostic utility of glycosyltransferase expression in breast cancer. *Cancer Genomics Proteomics*. 2008;5:333–40.
 44. Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T, et al. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. *Gastric Cancer*. 2016;19:85–97. <https://doi.org/10.1007/s10120-014-0454-z>.
 45. Kang JM, Park S, Kim SJ, Kim H, Lee B, Kim J, et al. KIAA1324 suppresses gastric Cancer progression by inhibiting the Oncoprotein GRP78. *Cancer Res*. 2015;75:3087–97. <https://doi.org/10.1158/0008-5472.CAN-14-3751>.
 46. Fan Y, Wang Y-F, Su H-F, Fang N, Zou C, Li W-F, et al. Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition. *J Hematol Oncol*. 2016;9:57. <https://doi.org/10.1186/s13045-016-0288-8>.
 47. Li D, Zhao X, Xiao Y, Mei H, Pu J, Xiang X, et al. Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer. *Oncotarget*. 2015;6:16168–82. <https://doi.org/10.18632/oncotarget.3753>.
 48. Edqvist P-HD, Huvila J, Forsström B, Talve L, Carpen O, Salvesen HB, et al. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. *Gynecol Oncol*. 2015;137: 529–37. <https://doi.org/10.1016/j.ygyno.2015.03.055>.
 49. Su J, Wu S, Tang W, Qian H, Zhou H, Guo T. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling. *Mol Carcinog*. 2016;55:1822–32. <https://doi.org/10.1002/mc.22430>.
 50. Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, et al. Development of ASG-15ME, a novel antibody–drug conjugate targeting SLITRK6, a new urothelial Cancer biomarker. *Mol Cancer Ther*. 2016;15.
 51. Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. *Cell Adhes Migr*. 2009;3:334–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

